Data on Disease Progression Reported by Researchers at Washington University (Using Health Insurance Claims Data To Assess Long-term Disease Progression In a Prostate Cancer Cohort): Disease Attributes – Disease Progression

2022 AUG 24 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- New research on Disease Attributes - Disease Progression is the subject of a report. According to news reporting from St. Louis, Missouri, by NewsRx journalists, research stated, “Long-term population-based cohort studies of men diagnosed with prostate cancer are limited. However, adverse outcomes can occur many years after treatment.”

Financial supporters for this research include American Cancer Society, University Cancer Research Fund via state of North Carolina, United States Department of Defense, Lineberger Comprehensive Cancer Center, University of North Carolina, NIH National Cancer Institute (NCI).

The news correspondents obtained a quote from the research from Washington University, “Herein, we aim to assess the utility of using claims data to identify prostate cancer progression 10-15 years after diagnosis. The study population was derived from the North Carolina-Louisiana Prostate Cancer Project (PCaP). PCaP-North Carolina (NC) included 1031 men diagnosed with prostate cancer from 2004 to 2009. An initial follow-up with a survey and manual medical record abstraction occurred from 2008 to 2011 (Follow-up 1). Herein, we extended this follow-up with linkage to healthcare claims data from North Carolina (2011-2017) and a second, supplementary 10-year follow-up survey (2018-2020) (Follow-up 2). Vital statistics data also were utilized. Long-term oncological progression was determined using these data sources in combination with expert clinical input. Among the 1031 baseline PCaP-NC participants, 652 were linked to medical claims. Forty-two percent of the men had insurance coverage for the entire 72 months of follow-up. In addition, 275 baseline participants completed the supplementary 10-year follow-up survey. Using all sources of follow-up data, we identified a progression event in 259 of 1031 (25%) men with more than 10 years of follow-up data after diagnosis. Understanding long-term clinical outcomes is essential for improving the lives of prostate cancer survivors. However, access and utility of long-term clinical outcomes with claims alone remain a challenge due to individualized agreements required with each insurer for data access, lack of detailed clinical information, and gaps in insurance coverage.”

According to the news reporters, the research concluded: “We were able to utilize claims data to determine long-term progression due to several unique advantages that included the availability of detailed baseline clinical characteristics and treatments, detailed manually abstracted clinical data at 5 years of follow-up, vital statistics data, and a supplementary 10-year follow-up survey.”

This research has been peer-reviewed.

For more information on this research see: Using Health Insurance Claims Data To Assess Long-term Disease Progression In a Prostate Cancer Cohort. The Prostate, 2022. The Prostate can be contacted at: Wiley, 111 River St, Hoboken 07030-5774, NJ, USA.

Our news journalists report that additional information may be obtained by contacting Saira Khan, Washington University, St. Louis School of Medicine, Division of Public Health Sciences, Dept. of Surgery, 660 S Euclid Ave, Msc 8100-0094-02300, St. Louis, MO 63110, United States. Additional authors for this research include Sanah Vohra, Jeannette T. Bensen, Laura Farnan, Shekinah N. C. Elmore, Khadijah Toumbou, K. C. Madhav, Elizabeth T. H. Fontham, Edward S. Peters and James L. Mohler.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1002/pros.24418. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)